Simon Z. He

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Hao Xiong, Yue Cui, T. Kipps, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CSL362: A Monoclonal Antibody to Human Interleukin-3 Receptor (CD123), Optimized for NK Cell-Mediated Cytotoxicity of AML Stem Cells

Angel F. Lopez, H. Ramshaw, A. Roberts, 2012 .

Nephrotic syndrome as a complication of chronic graft‐versus‐host disease after allogeneic haemopoietic stem cell transplantation

J. Szer, A. Roberts, M. Lasica, 2016, Internal medicine journal.

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

I. Kerridge, Angel F. Lopez, H. Ramshaw, 2015, Leukemia & lymphoma.

A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML

I. Lewis, P. Marlton, A. Roberts, 2008 .

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

H. Ramshaw, L. Fabri, A. Roberts, 2014, Leukemia.

Management of Patients With Erythropoietic Protoporphyria–Related Progressive Liver Disease

P. Angus, P. Gow, A. Testro, 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration

A. Grigg, A. Grigg, S. He, 2014, Internal medicine journal.

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

I. Lewis, P. Marlton, A. Schwarer, 2018, HemaSphere.

A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML.

I. Kerridge, I. Lewis, P. Marlton, 2010 .

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG

P. Marlton, A. Roberts, A. Wei, 2023, Blood.